Non-small Cell Lung Cancer
Conditions
Interventions
Observational group:None
Sponsors
Center for Drug Evaluation, National Medical Products Administration
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Step 1: Inclusion Criteria: 1. Pathologically diagnosed with locally advanced or recurrent/metastatic (Stage IIIB-IV) non-small cell lung cancer; 2. Age >= 18 years; 3. Has at least one record of drug administration (or prescription) after diagnosis of locally advanced or recurrent/metastatic non-small cell lung cancer, or with an interval of more than one month between two visits; 4. Carries one of the two common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R); 5. Has received EGFR-TKI therapy; 6. Has not undergone curative surgery or radiotherapy after diagnosis of locally advanced or recurrent/metastatic non-small cell lung cancer. Step 2: Inclusion and Exclusion Criteria: Based on the outcomes of Step 1, four sub-cohorts will be established respectively, each with detailed inclusion and exclusion criteria for matched RCTs.
Exclusion criteria
Exclusion criteria: Patients complicated with other types of solid tumors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Demographic characteristics;Clinical Characteristics;Treatment Patterns;Therapeutic outcome and prognosis; | — |
Countries
China
Contacts
Public ContactXin Xiaona
Center for Drug Evaluation, National Medical Products Administration
Outcome results
None listed